Nebenwirkungen · Lumigan
LUMIGAN 0.1 mg/ml eye drops, solution · Abschnitt 4.8 · PDF-Seite 6
HOS-109728 · Präparat HOS-093245
Prostaglandin analogues including LUMIGAN can induce periorbital lipodystrophic changes which can lead to deepening of the eyelid sulcus, ptosis, enophthalmos, eyelid retraction, involution of dermatochalasis and inferior scleral show. Changes are typically mild, can occur as early as one month after initiation of treatment with LUMIGAN, and may cause impaired field of vision even in the absence of patient recognition. PAP is also associated with periocular skin hyperpigmentation or discoloration and hypertrichosis. All changes have been noted to be partially or fully reversible upon discontinuation or switch to alternative treatments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-11-18T14:06:00Z · SHA-256 53709aeb7ae4918b6258ed233ae9c0bd61e40c01b7fc2e14ae82d0a3c8327635 · Passage 9f59d663fa805486dac2a4fbe26ef7a6679dfc6bf9fbf764183997d709268c39 · Zeichen 4151–4794 im Abschnitt